Ian Friedland, MD
Chief Medical Officer
Dr. Ian Friedland is a physician executive with over 25 years of clinical and industry experience in life sciences. A recognized leader in the development of anti-infectives he oversees the clinical strategy and regulatory pathways for Peptilogics’ innovative anti-biofilm platform.
Prior to joining Peptilogics, Dr. Friedland held several prominent roles, including chief medical officer at Achaogen and Calixa Therapeutics, and vice president of clinical development at Cubist Pharmaceuticals. His extensive career also includes senior leadership positions at Merck & Co. and Johnson & Johnson, where he directed global clinical programs from early-stage research through to late-stage pivotal trials and successful FDA designations.
Dr. Friedland is an expert in infectious disease research and has been instrumental in the development of numerous novel antibacterials. He earned his medical degree from the University of the Witwatersrand in Johannesburg and completed a fellowship in pediatric infectious diseases at UT Southwestern Medical School. He also completed residencies at Montefiore Hospital and Baragwanath Hospital.